CTMX Stock Surges to $8.50, Then Plummets Below $5 Post-Data

Shares of CTMX experienced significant volatility following the after-hours release of their latest data. The stock, initially priced at $3.99, surged to highs of $8.50, driven by positive early data that appeared more encouraging than competitor JANX's JANX008. Some traders sold half their positions at $9.00, securing profits. However, concerns about the effectiveness of CTMX's treatment in cancers other than pancreatic led to a sharp decline, with the stock plummeting back to below $5. This rapid change resulted in a roller coaster trading session, with some traders managing to secure profits over $8 before the drop.